TY - JOUR T1 - Clofazimine does not lead to significant QT interval prolongation: a multicentre study JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01386-2018 VL - 52 IS - 5 SP - 1801386 AU - Sanne M.H. Zweijpfenning AU - Hester van Groningen AU - Jakko van Ingen AU - Cecile Magis-Escurra AU - Martin J. Boeree AU - Dirk Wagner AU - Hannelore Bax AU - Claire Andrejak AU - Reinier Wener AU - Ananna Rahman AU - Heinke Kunst AU - Natalie Lorent AU - Marc A. Brouwer AU - Wouter Hoefsloot A2 - , Y1 - 2018/11/01 UR - http://erj.ersjournals.com/content/52/5/1801386.abstract N2 - We read with great interest the article by Pontali et al. [1], entitled “Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence”. In response to this paper and the debate on potential QTc prolongation in clofazimine- and bedaquiline-containing multidrug-resistant tuberculosis (MDR-TB) treatment regimens [2, 3], we assessed QTc prolongation during clofazimine use in treatment of disease caused by nontuberculous mycobacteria (NTM). This is important as NTM disease treatment typically includes multiple potential QTc-prolonging antibiotics, including macrolides, fluoroquinolones and, increasingly, clofazimine [4].Clofazimine does not lead to significant QT interval prolongation in the treatment of nontuberculous mycobacteria http://ow.ly/sXC330lIbI8 ER -